Supernus Pharmaceuticals SUPN Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Supernus Pharmaceuticals's change in AR?
- Supernus Pharmaceuticals (SUPN) reported change in AR of -$5.62M in Q1 2026.
- How has Supernus Pharmaceuticals's change in AR changed year-over-year?
- Supernus Pharmaceuticals's change in AR decreased by 257.7% year-over-year, from $3.56M to -$5.62M.
- What is the long-term trend for Supernus Pharmaceuticals's change in AR?
- Over 2 years (2022 to 2025), Supernus Pharmaceuticals's change in AR has grown at a 16.7% compound annual growth rate (CAGR), from $16.37M to $22.3M.
- What does change in AR mean?
- Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.